8f1213be-da41-4cd6-97b2-f9fce1ea00ff
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.600
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.480
- MTORC1_SIGNALING+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.450
- INFLAMMATORY_RESPONSE+0.430
- DNA_REPAIR+0.410
- MYC_TARGETS_V2+0.410
- ALLOGRAFT_REJECTION+0.400
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.460
- MYOGENESIS-0.240
- WNT_BETA_CATENIN_SIGNALING-0.200
- BILE_ACID_METABOLISM-0.160
- KRAS_SIGNALING_DN-0.140
- APICAL_SURFACE-0.130
- UV_RESPONSE_DN-0.110
- SPERMATOGENESIS-0.060
- APICAL_JUNCTION-0.040
- MITOTIC_SPINDLE-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313147 | — | E | 0.914 |
| 2 | TCGA-GC-A6I1-01A-12R-A31N-07 | — | — | 0.911 |
| 3 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.911 |
| 4 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.911 |
| 5 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.909 |
| 6 | BS_GJNCYABP | ATRT | — | 0.907 |
| 7 | SRR6013500 | — | cohortA1 | 0.906 |
| 8 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.905 |
| 9 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.905 |
| 10 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |